智通财经APP讯，白云山(600332.SH)公告，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂(简称“白云山制药总厂”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，药物名称BYS30颗粒。
根据《中华人民共和国药品管理法》及有关规定，经审查，2024年10月29日受理的BYS30颗粒(CXZL2400072)临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于膝骨关节炎的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.